IRADIMED director sells 1,000 shares in open trade

IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock.

Rhea-AI Filing Summary

IRADIMED CORP director Monty K. Allen reported an open-market sale of company stock. On 02/13/2026, he sold 1,000 shares of common stock in multiple trades at a weighted average price of $100.2563 per share. After this transaction, he directly owned 21,000 shares of IRADIMED CORP common stock.

Insider Trade Summary

Net Seller: 1,000 shares

Net Sell 1 txn

Insider ALLEN MONTY K

Role Director

Sold 1,000 shs ($100K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,000	$100.2563	$100K

Holdings After Transaction: Common Stock — 21,000 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IRADIMED CORP (IRMD) disclose for Monty K. Allen?

IRADIMED CORP disclosed that director Monty K. Allen sold 1,000 shares of common stock. The transaction occurred on February 13, 2026, in an open-market sale reported on Form 4, and was executed at a weighted average price of $100.2563 per share.

At what price did the IRADIMED CORP director sell his 1,000 shares?

The 1,000 IRADIMED CORP shares were sold at a weighted average price of $100.2563. The filing notes that multiple trades occurred at prices ranging from $100.00 to $100.26, and the reported figure represents the average sale price across those trades.

How many IRADIMED CORP shares does Monty K. Allen own after the reported sale?

After the reported transaction, Monty K. Allen beneficially owned 21,000 shares of IRADIMED CORP common stock directly. This figure reflects his holdings following the sale of 1,000 shares on February 13, 2026, as disclosed in the Form 4 filing.

What does the Form 4 transaction code 'S' mean in the IRADIMED CORP filing?

In the IRADIMED CORP Form 4, transaction code “S” indicates a sale in an open market or private transaction. Here, it shows that director Monty K. Allen disposed of 1,000 common shares on February 13, 2026, at a weighted average price of $100.2563.

Was the IRADIMED CORP insider transaction executed in a single trade or multiple trades?

The insider transaction was executed in multiple trades. The filing states that trades occurred at prices ranging from $100.00 to $100.26, and the reported $100.2563 per share represents the weighted average sale price for the 1,000 shares sold.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 03:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ALLEN MONTY K

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/13/2026		S		1,000	D	$100.2563(1)	21,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $100.00 to $100.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

	/s/ Monty K. Allen	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.